Cosmo Enters Scale Up Phase with 104M Revenue, 128M Cash, and Breakout AI and Dermatology Platforms @Cosmo_Pharma #HealthCare #OTC #OTCMarkets #OTCStocks #Investing
Ad hoc announcement pursuant to Art. 53 LR 2025 marks a key execution year in Cosmo’s Vision 2030, strengthening the Company’s foundations for scalable, innovation-driven growth across AI-enabled MedTech and pharma. Financial Highlights: High quality growth: €104 million revenue at guidance midpoint (€102 to €107 million) with recurring revenues representing the majority of sales and accelerating year over year ...
http://dlvr.it/TQHm8g
http://dlvr.it/TQHm8g
Comments
Post a Comment